Koers TrovaGene Inc Nasdaq
Aandelen
US8972383090
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 390K 359K | Omzet 2025 * | 66,67K 61,35K | Marktkapitalisatie | 158 mln. 146 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -45 mln. -41,41 mln. | Nettowinst (verlies) 2025 * | -57 mln. -52,45 mln. | EV/omzet 2024 * | 406 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2.375 x |
K/w-verhouding 2024 * |
-3,62
x | K/w-verhouding 2025 * |
-3,34
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,33% |
Recentste transcriptie over TrovaGene Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
James Levine
DFI | Director of Finance/CFO | 53 | 12-07-21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22-04-20 |
Gary Pace
BRD | Director/Board Member | 76 | 22-04-20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 54,04 mld. | |
-0,56% | 41,92 mld. | |
+47,64% | 41,96 mld. | |
-7,20% | 28,35 mld. | |
+12,59% | 26,35 mld. | |
-21,51% | 19 mld. | |
+6,92% | 13 mld. | |
+24,91% | 12,19 mld. | |
+29,60% | 12,28 mld. |